Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006, 4: 295-306. 10.1111/j.1538-7836.2006.01753.x.
CAS
PubMed
Google Scholar
Nielsen GL, Sorensen HT, Larsen H, Pedersen L: Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. Br Med J. 2001, 322: 266-270.
CAS
Google Scholar
Chan LY, Yuen PM: Risk of miscarriage in pregnant users of NSAIDs. More information is needed to be able to interpret study's results. Br Med J. 2001, 322: 1365-1366.
CAS
Google Scholar
Li DK, Liu L, Odouli R: Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. Br Med J. 2003, 327: 368-373.
CAS
Google Scholar
Kozer E, Moldovan Costei A, Boskovic R, Nulman I, Nikfar S, Koren G: Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. Birth Defects Res B Dev Reprod Toxicol. 2003, 68: 70-84. 10.1002/bdrb.10002.
CAS
PubMed
Google Scholar
Yussoff Dawood M: Nonsteroidal antiinflammatory drugs and reproduction. Am J Obstet Gynecol. 1993, 169: 1255-1265.
Google Scholar
Lewis RB, Schulman JD: Influence of acetylicsalicylic acid, an inhibitor of prostaglandin synthesis, on the duration of human gestation and labour. Lancet. 1973, ii: 1159-1161. 10.1016/S0140-6736(73)92934-6.
Google Scholar
Sawdy RJ, Lye S, Fisk NM, Bennett PR: A double-blind ran-domised study of fetal side effects during and after short-term maternal administration of indomethacin, sulindac, and nimesulide for therapy of preterm labor. Am J Obstet Gynecol. 2003, 188: 1046-1051. 10.1067/mob.2003.255.
CAS
PubMed
Google Scholar
Locatelli A, Vergani P, Bellini P, Strobelt N, Ghidini A: Can a cyclooxygenase type-2 selective tocolytic agent avoid the fetal side effects of indomethacin?. BJOG. 2001, 108: 325-326. 10.1016/S0306-5456(00)00071-1.
CAS
PubMed
Google Scholar
Stika CS, Gross GA, Leguizamon G, Gerber S, Levy R, Mathur A, Bernhard LM, Nelson DM, Sadovsky Y: A prospective randomized safety trial of celecoxib for treatment of preterm labor. Am J Obstet Gynecol. 2002, 187: 653-660. 10.1067/mob.2002.125281.
CAS
PubMed
Google Scholar
Cook JC, Jacobson CF, Gao F, Tassinari MS, Hurtt ME, DeSesso JM: Analysis of the nonsteroidal anti-inflammatory drug literature for potential developmental toxicity in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol. 2003, 68: 5-26. 10.1002/bdrb.10005.
CAS
PubMed
Google Scholar
Cappon GD, Cook JC, Hurtt ME: Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res B Dev Reprod Toxicol. 2003, 68: 47-56. 10.1002/bdrb.10008.
CAS
PubMed
Google Scholar
Heinonen OP, Slone D, Shapiro S: Birth Defects and Drugs in Pregnancy. 1977, Littleton, MA: Littleton Publishing Sciences Group, 286-295.
Google Scholar
Slone D, Heinonen OP, Kaufman DW, Siskind V, Monson RR, Shapiro S: Aspirin and congenital malformations. Lancet. 1976, ii: 1373-1375. 10.1016/S0140-6736(76)93025-7.
Google Scholar
Briggs GG, Freeman RK, Yaffe SJ, eds: Drugs in Pregnancy and Lactation. 2002, Philadelphia: Lippincott Williams & Wilkins, 6
Google Scholar
Källèn B: The teratogenicity of antirheumatic drugs – what is the evidence?. Scand J Rheumatol. 1998, 27 (Suppl 107): 119-124.
Google Scholar
Kozer E, Shekoufeh N, Costei A, Boskovic R, Nulman I, Koren G: Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol. 2002, 187: 1623-1630. 10.1067/mob.2002.127376.
PubMed
Google Scholar
Martinez-Frias ML, Rodriguez-Pinilla E, Prieto L: Prenatal exposure to salicylates and gastroschisis: a case-control study. Teratology. 1997, 56: 241-243. 10.1002/(SICI)1096-9926(199710)56:4<241::AID-TERA2>3.0.CO;2-1.
CAS
PubMed
Google Scholar
Stanfield KM, Bell RR, Lisowski AR, English ML, Saldeen SS, Khan KN: Expression of cyclooxygenase-2 in embryonic and fetal tissues during organogenesis and late pregnancy. Birth Defects Res A Clin Mol Teratol. 2003, 67: 54-58. 10.1002/bdra.10032.
CAS
PubMed
Google Scholar
Momma K, Takeuchi H: Constriction of the ductus arteriosus by non-steroidal anti-inflammatory drugs. Prostaglandins. 1983, 26: 631-643. 10.1016/0090-6980(83)90200-9.
CAS
PubMed
Google Scholar
Norton ME, Merril J, Cooper BAB, Kuller JA, Clyman RI: Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med. 1993, 329: 1602-1607. 10.1056/NEJM199311253292202.
CAS
PubMed
Google Scholar
Vermillion ST, Scardo JA, Lashus AG, Wiles HB: The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol. 1997, 177: 256-261. 10.1016/S0002-9378(97)70184-4.
CAS
PubMed
Google Scholar
Van den Veyver IB, Moise KJ, Ou CN, Carpenter RJ: The effect of gestational age and fetal indomethacin levels on the incidence of constriction of the fetal ductus arteriosus. Obstet Gynecol. 1993, 82: 500-503.
CAS
PubMed
Google Scholar
Norton ME: Fetal effects of indomethacin administration during pregnancy. Teratology. 1997, 56: 282-292. 10.1002/(SICI)1096-9926(199710)56:4<282::AID-TERA7>3.0.CO;2-0.
CAS
PubMed
Google Scholar
Alano MA, Ngougmna E, Ostrea EM, Konduri GG: Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics. 2001, 107: 519-513. 10.1542/peds.107.3.519.
CAS
PubMed
Google Scholar
Hickok DE, Hollenbach KA, Reilley SF, Nyberg DA: The association between decreased amniotic fluid volume and treatment with nonsteroidal anti-inflammatory agents for preterm labor. Am J Obstet Gynecol. 1989, 160: 1525-1531.
CAS
PubMed
Google Scholar
van der Heijden B, Gubler MC: Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr Nephrol. 1995, 9: 675-10.1007/BF00860975.
CAS
PubMed
Google Scholar
Llanas B, Cavert MH, Apere H, Demarquez JL: Les effets sec-ondaires du ketoprofène après exposition intra-utérine. Intérêt du dosage plasmatique. Arch Pediatr. 1996, 3: 248-253. 10.1016/0929-693X(96)81303-0.
CAS
PubMed
Google Scholar
Peruzzi L, Gianooglio B, Porcellini G, Conti G, Amoro A, Coppo R: Neonatal chronic kidney failure associated with cyclooxy-genase-2 inhibitors administered during pregnancy. Minerva Uro Nefrol. 2001, 53: 113-116.
CAS
Google Scholar
Stuart MJ, Gross SJ, Elrad H, Graeber JE: Effects of acetylsali-cylic-acid ingestion on maternal and neonatal hemostasis. N Engl J Med. 1982, 307: 909-912.
CAS
PubMed
Google Scholar
Hertz-Picciotto I, Hopenhayn-Rich C, Golub M, Hooper K: The risks and benefit of taking aspirin during pregnancy. Epidemiol Rev. 1990, 12: 108-148.
CAS
PubMed
Google Scholar
Di Sessa TG, Moretti ML, Khoury A, Pulliam DA, Arheart KL, Sibai BM: Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol. 1994, 171: 892-900.
CAS
PubMed
Google Scholar
Leonhardt A, Bernert S, Watzer B, Schmitz-Ziegler G, Seyberth HW: Low-dose aspirin in pregnancy: maternal and neonatal aspirin concentrations and neonatal prostanoid formation. Pediatrics. 2003, 111: e77-e81. 10.1542/peds.111.1.e77.
PubMed
Google Scholar
Horlocker TT, Bajwa ZH, Ashraf Z, Khan S, Wilson JL, Sami N, Peeters-Asdourian C, Powers CA, Schroeder DR, Decker PA, et al: Risk assessment of hemorrhagic complications associated with nonsteroidal antiinflammatory medications in ambulatory pain clinic patients undergoing epidural steroid injection. Anesth Analg. 2002, 95: 1691-1697. 10.1097/00000539-200212000-00041.
CAS
PubMed
Google Scholar
Reese J, Zhao X, Ma WG, Brown N, Maziasz TJ, Dey SK: Comparative analysis of pharmacologic and/or geneticdisruption of cyclooxygenase-1 and cyclooxygenase-2 function infemale reproduction in mice. Endocrinology. 2001, 142: 3198-3206. 10.1210/en.142.7.3198.
CAS
PubMed
Google Scholar
Sookvanichsilp N, Pulbutr P: Anti-implantation effects ofindomethacin and celecoxib in rats. Contraception. 2002, 65: 373-378. 10.1016/S0010-7824(01)00322-5.
CAS
PubMed
Google Scholar
Mendonca LLF, Khamashta MA, Nelson-Piercy C, Hughes GRV: Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology. 2000, 39: 880-882. 10.1093/rheumatology/39.8.880.
CAS
PubMed
Google Scholar
Uhler ML, Hsu JW, Fisher SG, Zinaman MJ: The effect ofnons-teroidal antiinflammatory drugs on ovulation: a prospective, randomized clinical trial. Fertil Steril. 2001, 76: 957-961. 10.1016/S0015-0282(01)02829-1.
CAS
PubMed
Google Scholar
Pall M, Friden BE, Brannstrom M: Induction of delayedfollicular rupture in the human by the selective COX-2 inhibitor rofe-coxib: a randomized double blind study. Hum Reprod. 2001, 16: 1323-1328. 10.1093/humrep/16.7.1323.
CAS
PubMed
Google Scholar
Martini AC, Molina RI, Tissera AD, Ruiz RD, DeCuneo MF: Analysis of semen from patients chronically treated with low or moderate doses of aspirin like drugs. Fertil Steril. 2003, 80: 221-222. 10.1016/S0015-0282(03)00550-8.
PubMed
Google Scholar
Østensen M: Safety of non-steroidal anti-inflammatorydrugs during pregnancy and lactation. Inflammopharmacology. 1996, 4: 31-41.
Google Scholar
Spigset O, Hägg S: Analgesics and breast-feeding. Safety considerations. Paediatr Drugs. 2000, 2: 223-238. 10.2165/00128072-200002030-00006.
CAS
PubMed
Google Scholar
Committee on Drugs. American Academy of Pediatrics: The transfer of drugs and other chemicals into human milk. Pediatrics. 2001, 108: 776-789.
Google Scholar
Derksen RHW, Khamashta MA, Branch DW: Management of theobstetric antiphospholipid syndrome. Arthritis Rheum. 2004, 50: 1028-1039. 10.1002/art.20105.
CAS
PubMed
Google Scholar
Empson M, Lassere M, Craig J, Scott J: Prevention ofrecurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant [review]. Cochrane Database Syst Rev. 2005, 2: CD002859-
PubMed
Google Scholar
Nguyen CM, Harrington RA: Glycoprotein IIb/IIIa receptorantagonists: a comparative review of their use in percutaneous coronary intervention. Am J Cardiovasc Drugs. 2003, 3: 23-10.2165/00129784-200303060-00005.
Google Scholar
The Matisse Investigators: Subcutaneous Fondoparinuxversus intravenous unfractioned heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003, 349: 1695-1702. 10.1056/NEJMoa035451.
Google Scholar
Turpie AG, Eriksson BI, Bauer KA, Lassen MR: New pentasac-charides for the prophylaxis of venous thromboembolism. Chest. 2003, 124: 371S-378S. 10.1378/chest.124.6_suppl.371S.
CAS
PubMed
Google Scholar
Dempfle CEH: Minor transplacental passage of fondoparinux in vivo. N Engl J Med. 2004, 350: 1914-1915. 10.1056/NEJM200404293501825.
CAS
PubMed
Google Scholar
Olsson SB Executive Steering Committee on behalf of the SPORTIF III investigators: Stroke prevention with the oral direct thrombion inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet. 2003, 362: 1691-1698. 10.1016/S0140-6736(03)14841-6.
Google Scholar
Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, THRIVE Treatment Study Investigators: Ximelagatran vs low-molecular-weight heparin and war-farin for the treatment of deep vein thrombosis: a randomized trial. JAMA. 2005, 293: 681-689. 10.1001/jama.293.6.681.
CAS
PubMed
Google Scholar
Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, EXULT A Study Group: Comparison ofximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003, 349: 1703-1712. 10.1056/NEJMoa035162.
CAS
PubMed
Google Scholar
Benediktsson R, Calder AA, Edwards CRW, Seckl JR: Placental 11b-hydroxysteroid dehydrogenase: a key regulatorof fetal glucocorticoid exposure. Clin Endocrinol. 1997, 46: 161-166. 10.1046/j.1365-2265.1997.1230939.x.
CAS
Google Scholar
Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L: Repeated fetal losses associated with antiphospholipid antibodies; a collaborative randomized trial comparing pred-nisone with low-dose heparin treatment. Am J Obstet Gynecol. 1992, 166: 1318-1323.
CAS
PubMed
Google Scholar
Pinsky L, DiGeorge AM: Cleft palate in the mouse: a teratogenic index of glucocorticoid potency. Science. 1965, 147: 402-403.
CAS
PubMed
Google Scholar
Reinisch JM, Simon NG: Prenatal exposure to prednisone inhumans and animals retards intrauterine growth. Science. 1978, 202: 436-438.
CAS
PubMed
Google Scholar
Rodriguez-Pinilla E, Martinez-Frias ML: Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology. 1998, 58: 2-5. 10.1002/(SICI)1096-9926(199807)58:1<2::AID-TERA2>3.0.CO;2-4.
CAS
PubMed
Google Scholar
Carmichael SL, Shaw GM: Maternal corticosteroid use andrisk of selected congenital anomalies. Teratology. 1999, 86: 242-244.
CAS
Google Scholar
Pradat P, Robert-Gnansia E, Di Tanna GL, Rosano A, Lisi A, Mastroiacovo P, Contributors to the MADRE database: First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol. 2003, 67: 968-970. 10.1002/bdra.10134.
CAS
PubMed
Google Scholar
Czeizel AE, Rockenbauer M: Population-based case-controlstudy of teratogenic potential of corticosteroids. Teratology. 1997, 56: 335-340. 10.1002/(SICI)1096-9926(199711)56:5<335::AID-TERA7>3.0.CO;2-W.
CAS
PubMed
Google Scholar
Fraser FC, Sajoo A: Teratogenic potential of corticosteroids in humans. Teratology. 1995, 51: 45-46. 10.1002/tera.1420510107.
CAS
PubMed
Google Scholar
Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, Friesen MH, Jacobson S, Kasapinovic S, Chang D, et al: Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiologi-cal studies. Teratology. 2000, 62: 385-392. 10.1002/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z.
CAS
PubMed
Google Scholar
Källén B: Maternal drug use and infant cleft lip/palatewith special reference to corticoids. Cleft Pal Craniofacial J. 2003, 40: 624-628. 10.1597/02-077.
Google Scholar
Scott JR: Fetal growth retardation associated withmaternal administration of immunosuppressives. Am J Obstet Gynecol. 1977, 128: 668-676.
CAS
PubMed
Google Scholar
Czeizel AE, Toth M: Birth weight, gestational age and medications during pregnancy. Int J Gynaecol Obstet. 1998, 60: 245-249. 10.1016/S0020-7292(97)00273-7.
CAS
PubMed
Google Scholar
Schmidt PL, Sims ME, Strassner HT, Paul RH, Mueller E, McCart D: Effect of antepartum glucorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. Am J Obstet Gynecol. 1984, 178: 178-186.
Google Scholar
Cederqvist LL, Merkatz IR, Litwin SD: Fetal immunoglobinsynthesis following maternal immunosuppression. Am J Obstet Gynecol. 1977, 129: 687-690.
CAS
PubMed
Google Scholar
Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CRW: Glucocorticoid exposure in utero: new model for adult hypertension. Lancet. 1993, 341: 339-341. 10.1016/0140-6736(93)90138-7.
CAS
PubMed
Google Scholar
Kraus AM: Congenital cataract and maternal steroidinjection. J Pediatr Ophthalmol Strabismus. 1975, 12: 107-108.
Google Scholar
Coté CJ, Meuwissen HG, Pickering RJ: Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatrics. 1974, 85: 324-328.
Google Scholar
Price HV, Salaman JR, Laurence KM, Langmaid H: Immunusuppressive drugs and the fetus. Transplantation. 1976, 21: 294-298.
CAS
PubMed
Google Scholar
National Institutes of Health: Report of the ConsensusDevelopment Conference on the Effect of Corticosteroids for FetalMaturation on Perinatal Outcome. NIH Publication no. 95–3784. 1994, Bethesda, MD: National Institute of Child Health and Human Development
Google Scholar
Huang WL, Haper CG, Evans SF, Newnham JP, Dunlop SA: Repeated prenatal corticosteroid administration delays astro-cyte and capillary tight junction maturation in fetal sheep. Int J Dev Neurosci. 2000, 19: 487-493. 10.1016/S0736-5748(01)00035-1.
Google Scholar
Matthews SG: Antenatal glucocorticoids and programming of the developing CNS. Pediatr Res. 2000, 47: 291-300.
CAS
PubMed
Google Scholar
Jobe AH, Wada N, Berry LM, Ikegami M, Ervin MG: Singleand repetitive maternal glucocorticoid exposures reduce fetal growthin sheep. Am J Obstet Gynecol. 1998, 178: 880-885. 10.1016/S0002-9378(98)70518-6.
CAS
PubMed
Google Scholar
French NP, Hagan R, Evans SF, Godfrey M, Newnham JP: Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol. 1999, 180: 114-121. 10.1016/S0002-9378(99)70160-2.
CAS
PubMed
Google Scholar
Abbasi S, Hirsch D, Davis J, Stouffer N, Debbs R, Gerdes JS: Effect of single versus multiple courses of antenatal corticos-teroids on maternal and neonatal outcome. Am J Obstet Gynecol. 2000, 182: 1243-1249. 10.1067/mob.2000.104789.
CAS
PubMed
Google Scholar
Spinillo A, Viazzo F, Colleoni R, Chiara A, Cerbo RA, Fazzi E: Two-year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity. Am J Obstet Gynecol. 2004, 191: 217-224. 10.1016/j.ajog.2003.12.023.
CAS
PubMed
Google Scholar
National Institutes of Health: Antenatal corticosteroid revisited: repeat courses. NIH Consensus Statement. 2000, 17: 1-18.
Google Scholar
Urban R, Lemancewicz A, Przepiesc J, Urban J, Kretowska M: Antenatal corticosteroid therapy: a comparative study of dex-amethasone and betamethasone effects on fetal Doppler flow velocity waveforms. Eur J Obstet Gynecol Reprod Biol. 2005, 120: 170-174. 10.1016/j.ejogrb.2004.09.009.
CAS
PubMed
Google Scholar
Crowley P: Prophylactic corticosteroids for pretermdelivery. Cochrane Database Syst Rev. 2000, 2: CD000065-
PubMed
Google Scholar
Jobe AH, Soll RF: Choice and dose of corticosteroid forantenatal treatments. Am J Obstet Gynecol. 2004, 190: 871-885. 10.1016/j.ajog.2004.01.044.
Google Scholar
Lodygensky GA, Rademaker K, Zimine S, Gex-Fabry M, Lieftink AF, Lazeyras F, Groenendaal F, de Vries LS, Huppi PS: Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics. 2005, 116: 1-7. 10.1542/peds.2004-1275.
PubMed
Google Scholar
Katz FH, Duncan BR: Entry of prednisone into human milk. N Engl J Med. 1975, 293: 1154-
CAS
PubMed
Google Scholar
Öst L, Wettrell G, Bjorkhem I, Rane A: Prednisolone excretion in L, human milk. J Pediatrics. 1985, 106: 1008-1011. 10.1016/S0022-3476(85)80259-6.
Google Scholar
Ruiz-Irastorza G, Khamashta MA, Hughes GR: Heparin and osteoporosis during pregnancy: 2002 update. Lupus. 2002, 11: 680-682. 10.1191/0961203302lu262oa.
CAS
PubMed
Google Scholar
Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A: Transplacental effcts of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology. 1999, 60: 68-73. 10.1002/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H.
CAS
PubMed
Google Scholar
Dunlop DJ, Soukop M, McEwan HP: Antenatal administrationof aminopropylidene diphosphonate. Ann Rheum Dis. 1990, 49: 955-
PubMed Central
CAS
PubMed
Google Scholar
Illidge TM, Hussey M, Godden CW: Malignanthypercalciaemia – in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol. 1996, 8: 257-258. 10.1016/S0936-6555(05)80667-3.
CAS
Google Scholar
Rutgers-Verhage AR, de Vries TW, Torringa MJL: No effects of bisphosphonates on the human fetus. Birth Defects Res A. 2003, 67: 203-204. 10.1002/bdra.10016.
CAS
Google Scholar
Siminoski K, Fitzgerald AA, Flesch G, Gross MS: Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding. J Bone Miner Res. 2000, 15: 2052-2055. 10.1359/jbmr.2000.15.10.2052.
CAS
PubMed
Google Scholar
Phillips-Howard PA, Wood D: The safety of antimalarial drugs in pregnancy. Drug Safety. 1996, 14: 131-145.
CAS
PubMed
Google Scholar
Costedoat-Chalumeau N, Amoura Z, Aymard G, Huong DLT, Wechsler B, Vauthier D, Dermer ME, Darbois Y, Piette JC: Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum. 2002, 46: 1123-1124. 10.1002/art.10150.
PubMed
Google Scholar
Wolfe MS, Cordero J: Safety of chloroquine in chemosuppression of malaria during pregnancy. Br Med J. 1985, 290: 1466-1467.
CAS
Google Scholar
Levy M, Buskila D, Gladman DD, Urowitz MB, Koren G: Pregnancy outcome following first trimester exposure to chloro-quine. Am J Perinatol. 1991, 8: 174-178.
CAS
PubMed
Google Scholar
Parke AL: Antimalarial drugs, systemic lupus erythematosus and pregnancy. J Rheumatol. 1988, 15: 607-610.
CAS
PubMed
Google Scholar
Parke AL, West B: Hydoxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol. 1996, 23: 1715-1718.
CAS
PubMed
Google Scholar
Buchanan NMM, Toubi E, Khamashta KE, Lima F, Kerslake S, Hughes GRV: Hydoxychloroquine and lupus pregnancy: review Jof a series of 36 cases. Ann Rheum Dis. 1996, 55: 486-488.
PubMed Central
CAS
PubMed
Google Scholar
Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong DLT, Seb-bough D, Wechsler B, Vauthier D, Denjoy I, Lupoglazoff JM, Piette JC: Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 2003, 48: 3207-3211. 10.1002/art.11304.
CAS
PubMed
Google Scholar
Borden MB, Parke AL: Antimalarial drugs in systemic lupus – erythematosus. Use in pregnancy. Drug Safety. 2001, 24: 1055-1063. 10.2165/00002018-200124140-00004.
CAS
PubMed
Google Scholar
Hart CN, Naunton RF: The ototoxicity of chloroquine phosphate. Arch Otolaryngol Head Neck Surg. 1964, 80: 407-412.
CAS
Google Scholar
Akintonwa A, Gbajumo SA, Mabadeje AFB: Placental and milk transfer of chloroquine in humans. Ther Drug Monit. 1988, 10: 147-149.
CAS
PubMed
Google Scholar
Nation RL, Hackett LP, Dusci LJ, Ilett KF: Excretion of hydroxychloroquine in human milk. Br J Clin Pharmacol. 1984, 17: 368-369.
PubMed Central
CAS
PubMed
Google Scholar
Østensen M, Brown ND, Chiang PK, Aarbakke J: Hydroxychloro-quine in human breast milk. Br J Clin Pharmacol. 1985, 28: 357-
Google Scholar
Klinger G, Morad Y, Westall CA, Laskin C, Spitzer KA, Koren G, Ito S, Buncic RJ: Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet. 2001, 358: 813-814. 10.1016/S0140-6736(01)06004-4.
CAS
PubMed
Google Scholar
Motta M, Tincani A, Faden D, Zinzini E, Lojacono A, Marchesi A, Frassi M, Biasini C, Zatti S, Chirico G: Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol. 2005, 25: 86-89. 10.1038/sj.jp.7211208.
CAS
PubMed
Google Scholar
Cimaz R, Brucato A, Meregalli E, Muscarà M, Sergi P: Electroretinograms of children born to mothers treated with hydroxychloroquine (HCQ) during pregnancy and breast-feeding. Arthritis Rheum. 2004, 50: 3056-3057. 10.1002/art.20648.
PubMed
Google Scholar
Borba EF, Turrini-Filho JR, Kuruma KA, Bertola C, Pedalini ME, Lorenzi MC, Bonfa E: Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry. Lupus. 2004, 13: 223-227. 10.1191/0961203304lu528oa.
CAS
PubMed
Google Scholar
Norgard B, Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT: Population based case control study of the safety of sul-phasalazine used during pregnancy. Aliment Pharmacol Ther. 2001, 15: 483-486. 10.1046/j.1365-2036.2001.00962.x.
CAS
PubMed
Google Scholar
Mogadam M, Dobbins WO, Korelitz BI, Ahmed SW: Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology. 1981, 80: 72-76.
CAS
PubMed
Google Scholar
Järnerot G: Fertility, sterility and pregnancy in chronic inflammatory bowel disease. Scand J Gastroenterol. 1982, 17: 1-4.
PubMed
Google Scholar
Nielsen OH, Andreasson B, Bondesen S, Jarnum S: Pregnancy in ulcerative colitis. Scand J Gastroenterol. 1993, 18: 735-742.
Google Scholar
Baocco PJ, Korelitz BI: The influence of inflammatorybowel disease and its treatment on pregnancy and on fetal outcome. J Clin Gastroenterol. 1984, 6: 211-216.
Google Scholar
Willoughby CP, Truelobe SC: Ulcerative colitis andpregnancy. Gut. 1980, 21: 469-474.
PubMed Central
CAS
PubMed
Google Scholar
Moody GA, Probert C, Jayanthi V, Mayberry JF: The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire. Int J Colorect Dis. 1997, 12: 220-224. 10.1007/s003840050093.
CAS
Google Scholar
Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA: Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000, 343: 1608-1614. 10.1056/NEJM200011303432204.
CAS
PubMed
Google Scholar
Järnerot G, Anderson S, Esbjörner E, Sandström B, Brodersen R: Albumin reserve for binding of bilirubin in maternal and cord serum under treatment with sulphasalazine. Scand J Gastroenterol. 1981, 16: 1049-1055.
PubMed
Google Scholar
Zwi LJ, Becroft DM: Intrauterine aplastic anemia andfetal hydrops: a case report. Pediatr Pathol. 1986, 5: 199-205.
CAS
PubMed
Google Scholar
Levi S, Libermann M, Levi AJ, Bjarnason I: Reversible congenital neutropenia associated with maternal sulphasalazine therapy. Eur J Pediat. 1988, 148: 174-175. 10.1007/BF00445938.
CAS
Google Scholar
Esbjörner E, Järnerot G, Wranne L: Sulphasalazine andsul-phapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand. 1987, 76: 137-142.
PubMed
Google Scholar
Branski D, Kerem E, Gross-Kieselstein E, Hurvitz H, Litt R, Abrah-mav A: Bloody diarrhoea – a possible complication of sul-phasalazine transferred through human breast milk. J Pediat Gastroenterol Nutr. 1986, 5: 316-317.
CAS
Google Scholar
O'Morain C, Smethurst P, Doré CJ, Levi AJ: Reversible male infertility due to sulphasalazine: studies in man and rat. Gut. 1984, 25: 1078-1084.
PubMed Central
PubMed
Google Scholar
Brent RL: Teratogen update: reproductive risks of leflunomide (Arava). A pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology. 2001, 63: 106-112. 10.1002/1096-9926(200102)63:2<106::AID-TERA1017>3.0.CO;2-R.
CAS
PubMed
Google Scholar
Chakravarty EF, Sanchez-Yamamoto D, Bush TM: The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcome. J Rheumatol. 2003, 30: 241-246.
PubMed
Google Scholar
Polifka JE, Friedman JM: Teratogen update: azathioprine and 6-mercaptopurine. Teratology. 2002, 65: 240-261. 10.1002/tera.10043.
CAS
PubMed
Google Scholar
Reimers TJ, Sluss PM: 6-Mercaptopurine treatment ofpregnant mice: effect on second and third generation. Science. 1978, 201: 65-67.
CAS
PubMed
Google Scholar
The Registration Committee of the European Dialysis andTransplant Association: Successful pregnancies in women treated by dialysis and kidney transplantation. Br J Obstet Gynaecol. 1980, 87: 839-845.
Google Scholar
Alstead EM, Ritchie JK, Leonard-Jones JE, Farthing MJG: Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology. 1990, 99: 443-446.
CAS
PubMed
Google Scholar
Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, Present DH: The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol. 2004, 99: 656-661. 10.1111/j.1572-0241.2004.04140.x.
PubMed
Google Scholar
Price HV, Salaman JR, Laurence KM, Langmaid H: Immunusuppressive drugs and the fetus. Transplantation. 1976, 21: 294-298.
CAS
PubMed
Google Scholar
Coté CJ, Meuwissen HG, Pickering RJ: Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatrics. 1974, 85: 324-328.
Google Scholar
Davison JM, Dellagrammatikas H, Parkin JM: Maternal azathio-prine therapy and depressed haemopoiesis in the babies of renal allograft patients. Br J Obstet Gynaecol. 1985, 92: 233-239.
CAS
PubMed
Google Scholar
Rajapakse RO, Korelitz BI, Zlatank I, Baiocco PJ, Gleim GW: Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol. 2000, 95: 684-688. 10.1111/j.1572-0241.2000.01846.x.
CAS
PubMed
Google Scholar
Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH: The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003, 124: 9-17. 10.1053/gast.2003.50014.
CAS
PubMed
Google Scholar
Bennett PN: Azathioprine. Drugs and Human Lactation. Edited by: Bennett PN. 1988, Amsterdam: Elsevier, 286-287.
Google Scholar
Dejaco C, Mittermaier C, Reinisch W, Gasche C, Waldhoer T, MoserH Stroemer G: Azathioprine treatment and male infertility in inflammatory bowel disease. Gastroenterology. 2001, 121: 1048-1053. 10.1053/gast.2001.28692.
CAS
PubMed
Google Scholar
Pilarski LM, Yacyshyn BR, Lazarovits AI: Analysis of peripheral blood lymphocyte populations and immune function from children exposed to cyclosporine or to azathioprine in utero. Transplantation. 1994, 57: 133-144.
CAS
PubMed
Google Scholar
Scott JR, Branch WD, Holman J: Autoimmune and pregnancy complications in the daughter of a kidney transplant patient. Transplantation. 2002, 73: 815-816. 10.1097/00007890-200203150-00028.
PubMed
Google Scholar
Schröder H, Fogh K: Methotrexate and its polyglutamatederivates in erythrocytes during and after weekly low-dose oralmethotrexate therapy of children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol. 1988, 21: 145-149.
PubMed
Google Scholar
Wilson JG, Scott WJ, Ritter EJ, Fradkin R: Comparativedistribution and embryo toxicity of methotrexate in pregnant rats and rhesus monkeys. Teratology. 1979, 19: 71-98. 10.1002/tera.1420190111.
PubMed
Google Scholar
Milunsky A, Graef JW, Gaynor MF: Methotrexate-induced congenital malformations. J Pediatrics. 1968, 72: 790-795. 10.1016/S0022-3476(68)80430-5.
CAS
Google Scholar
Chapa JB, Hibbard JU, Weber EM, Abramowicz JS, Verp MS: Prenatal diagnosis of methotrexate embryopathy. Obstet Gynecol. 2003, 101: 1104-1107. 10.1016/S0029-7844(03)00120-0.
PubMed
Google Scholar
Powell HR, Eckert H: Methotrexate-induced congenital malformations. Med J Aust. 1971, 2: 1076-1077.
CAS
PubMed
Google Scholar
Schleuning M, Clemm C: Chromosomal aberrations in a newborn whose mother received cytotoxic treatment during pregnancy. N Engl J Med. 1987, 317: 1666-1667.
CAS
PubMed
Google Scholar
Pizzuto J, Aviles A, Noriega L, Niz J, Morales M, Romero F: Treatment of acute leukemia during pregnancy: presentation of nine cases. Cancer Treat Rep. 1980, 64: 679-683.
CAS
PubMed
Google Scholar
Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM: Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med. 1990, 88: 589-592. 10.1016/0002-9343(90)90522-F.
CAS
PubMed
Google Scholar
Feldkamp M, Carey JC: Clinical teratology counseling andconsultation case report: low dose methotrexate exposure in earlyweeks of pregnancy. Teratology. 1993, 47: 533-539. 10.1002/tera.1420470605.
CAS
PubMed
Google Scholar
Donnenfeld AE, Pastuszak A, Salkoff Noah J, Schick B, Rose NC, Koren G: Methotrexate exposure prior to and during pregnancy. Teratology. 1994, 49: 79-81. 10.1002/tera.1420490202.
CAS
PubMed
Google Scholar
Buckley LM, Bullaboy CA, Leichtman L, Marquez M: Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum. 1997, 40: 971-973.
CAS
PubMed
Google Scholar
Østensen M, Hartmann H, Salvesen K: Low dose weeklymethotrexate in early pregnancy. A case series and review of the literature. J Rheumatol. 2000, 27: 1872-1875.
PubMed
Google Scholar
Krähenmann F, Østensen M, Stallmach Th, Huch A, Chaoui R: In utero first trimester exposure to low-dosemethotrexate with increased fetal nuchal translucency and associatedmalformations. Prenat Diagn. 2002, 22: 489-490. 10.1002/pd.334.
PubMed
Google Scholar
Rustin GJS, Booth M, Dent J, Salt S, Rustin F, Bagshawe KD: Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. Br Med J. 1984, 288: 103-106.
CAS
Google Scholar
Gervaise A, Masson L, de Tayrac R, Frydman R, Fernandez H: Reproductive outcome after methotrexate treatment of tubal pregnancies. Obstet Gynecol Surv. 2005, 60: 175-176. 10.1097/01.ogx.0000156073.30008.1a.
Google Scholar
Green DM, Zevon MA, Lowrie G, Seigelstein N, Hall B: Congenital anomalies in children of patients who received chemotherapy for cancer in childhood and adolescence. N Engl J Med. 1991, 325: 141-146.
CAS
PubMed
Google Scholar
Johns DG, Rutherford LD, Keighton PC, Vogel CL: Secretion of methotrexate into human milk. Am J Obstet Gynecol. 1972, 112: 978-980.
CAS
PubMed
Google Scholar
Morris LF, Harrod MJ, Menter MA, Silverman AK: Methotrexate and reproduction in men: Case report and recommendations. J Am Acad Dermatol. 1993, 29: 913-916.
CAS
PubMed
Google Scholar
Sussman A, Leonard JM: Psoriasis, methotrexate, and oligospermia. Arch Dermatol. 1980, 116: 215-217. 10.1001/archderm.116.2.215.
CAS
PubMed
Google Scholar
Aviles A, Diaz-Maqueo JC, Talavera A, Guzman R, Garcia EL: Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children. Am J Hematol. 1991, 36: 243-248.
CAS
PubMed
Google Scholar
Mirkes PE: Cyclophosphamide teratogenesis. A review. Teratogen Carcinogen Mutagen. 1985, 5: 75-88. 10.1002/tcm.1770050202.
CAS
Google Scholar
Greenberg LH, Tanaka KR: Congenital anomalies probablyinduced by cyclophosphamide. JAMA. 1964, 188: 423-426.
CAS
PubMed
Google Scholar
Toledo TM, Harper RC, Moser RH: Fetal effects duringcyclophosphamide and irradiation therapy. Ann Intern Med. 1971, 74: 87-91.
CAS
PubMed
Google Scholar
Murray CL, Reichert JA, Anderson J, Twiggs LB: Multimodal cancer therapy for breast cancer in the first trimester of pregnancy. A case report. JAMA. 1984, 252: 2607-2608. 10.1001/jama.252.18.2607.
CAS
PubMed
Google Scholar
Kirshon B, Wasserstrum N, Willis R, Herman GE, McCabe ER: Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol. 1988, 72: 462-464.
CAS
PubMed
Google Scholar
Zemlickis D, Lishner M, Erlich R, Koren G: Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophos-phamide. Teratogen Carcinogen Mutagen. 1993, 13: 139-143. 10.1002/tcm.1770130304.
CAS
Google Scholar
Zemlickis D, Lishner M, Degendorfer P, Panzarella T, Sutcliffe SB, Koren G: Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med. 1992, 152: 573-576. 10.1001/archinte.152.3.573.
CAS
PubMed
Google Scholar
Enns GM, Roeder E, Chan RT, Ali-Khan Catts Z, Cox VA, Golabi M: Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype?. Am J Med Genet. 1999, 86: 237-241. 10.1002/(SICI)1096-8628(19990917)86:3<237::AID-AJMG8>3.0.CO;2-V.
CAS
PubMed
Google Scholar
Paladini D, Vassallo M, D'Armiento MR, Cianciaruso B, Martinelli P: Prenatal detection of multiple fetal anomalies following inadvertent exposure to cyclophosphamide in the first trimester of pregnancy. Birth Defects Res A Clin Mol Teratol. 2004, 70: 99-100. 10.1002/bdra.10147.
CAS
PubMed
Google Scholar
Vaux KK, Kahole NC, Jones KL: Cyclophosphamide, methotrex-ate, and cytarabine embropathy: is apoptosis the common pathway?. Birth Defects Res A Clin Mol Teratol. 2003, 67: 403-408. 10.1002/bdra.10060.
CAS
PubMed
Google Scholar
Durodola JI: Administration of cyclophosphamide during late pregnancy and early lactation: a case report. J Nat Med Ass. 1979, 71: 165-166.
PubMed Central
CAS
PubMed
Google Scholar
Gershenson DM: Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol. 1988, 6: 270-275.
CAS
PubMed
Google Scholar
Green DM, Whitton JA, Stovall M, Mertens AC, Donaldson SS, Ruymann FB, Pendergrass TW, Robison LL: Pregnancy outcome ofpartners of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2003, 21: 716-721. 10.1200/JCO.2003.04.085.
PubMed
Google Scholar
Wiernik PH, Duncan JH: Cyclophosphamide in human milk. Lancet. 1971, i: 912-10.1016/S0140-6736(71)92474-3.
Google Scholar
Waxman J: Chemotherapy and the adult gonad: a review. J R Soc Med. 1983, 76: 144-148.
PubMed Central
CAS
PubMed
Google Scholar
Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE: Risk of sustained amenorrhea in patients with systemiclupus erythematosus receiving intermittent pulse cyl-cophosphamidetherapy. Ann Intern Med. 1993, 119: 366-369.
CAS
PubMed
Google Scholar
Huong DLT, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, Piette JC: Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol. 2002, 29: 2571-2576.
CAS
PubMed
Google Scholar
Silva CAA, Hallak J, Pasqualotto FF, Barba MF, Saito MI, Kiss MHB: Gonadal function in male adolescents and young males with juvenile onset systemic lupus erythematosus. J Rheumatol. 2002, 29: 2000-2005.
PubMed
Google Scholar
Kenney LB, Laufer MR, Grant FD, Grier H, Diller L: High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer. 2001, 91: 613-621. 10.1002/1097-0142(20010201)91:3<613::AID-CNCR1042>3.0.CO;2-R.
CAS
PubMed
Google Scholar
Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ: Use of a gonadotropin-releasing hormone analog against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 2005, 52: 2761-2767. 10.1002/art.21263.
CAS
PubMed
Google Scholar
Winter JF, Boice JD, Mulvihill JJ, Stovall M, Frederiksen K, Tawn EJ, Olsen JH: Chromosomal abnormalities among offspring of child-cancer survivors in Denmark: a population based study. Am J Hum Genet. 2004, 74: 1282-1285. 10.1086/421473.
Google Scholar
Mason RJ, Thomson AW, Whiting PH, Gray ES, Brown PA, Catto GRD, Simpson JG: Cyclosporine-induced fetotoxicity in the rat. Transplantation. 1985, 39: 9-12.
CAS
PubMed
Google Scholar
Cockburn I, Krupp P, Monka C: Present experience of Sandim-mun in pregnancy. Transplant Proc. 1989, 21: 3730-3732.
CAS
PubMed
Google Scholar
Hussein MM, Mooij JMV, Roujouleh H: Cyclosporine in the treatment of lupus nephritis including 2 patients treated during pregnancy. Clin Nephrol. 1993, 40: 160-163.
CAS
PubMed
Google Scholar
Armenti VT, Ahlswede KM, Ahlswede BA, Jarrell BE, Moritz MJ, Burke JF: National transplantation pregnancy registry:outcomes of 154 pregnancies in cyclosporine-treated female kidneytransplant recipients. Transplantation. 1994, 57: 502-506.
CAS
PubMed
Google Scholar
Lamarque V, Leleu MF, Monka C, Krupp P: Analysis of 629 pregnancy outcomes in transplant recipients treated with Sandim-mun. Transplant Proc. 1997, 29: 2480-10.1016/S0041-1345(97)00458-2.
CAS
PubMed
Google Scholar
Barrou BM, Gruessner AC, Sutherland DE, Gruessner RW: Pregnancy after pancreas transplantation in the cyclosporin era: report from the International Pancreas Transplant Registry. Transplantation. 1998, 65: 524-527. 10.1097/00007890-199802270-00012.
CAS
PubMed
Google Scholar
Shaheen FAM, AI-Sulaiman MH, AI-Khader AA: Long-termnephrotoxicity after exposure to CsA in utero. Transplantation. 1993, 56: 224-225.
CAS
PubMed
Google Scholar
Bar Oz B, Hackman R, Einarson T, Koren G: Pregnancy outcome after CsA therapy during pregnancy: a meta-analysis. Transplantation. 2001, 71: 1051-1055. 10.1097/00007890-200104270-00006.
CAS
PubMed
Google Scholar
Moretti ME, Sgro M, Johnson DW, Sauve RS, Woolgar MJ, Taddio A, Verjee Z, Giesbrecht E, Koren G, Ito S: Cyclosporine excretion into breast milk. Transplantation. 2003, 75: 2144-2146. 10.1097/01.TP.0000066352.86763.D0.
CAS
PubMed
Google Scholar
Stanley CW, Gottlieb R, Zager R, Eisenberg J, Richmond R, Moritz MJ, Armenti VT: Developmental well-being in offspring of women receiving post-renal transplant. Transplant Proc. 1999, 31: 241-242. 10.1016/S0041-1345(98)01519-X.
CAS
PubMed
Google Scholar
Di Paolo S, Schena A, Morrone LF, Manfredi G, Stallone G, Derosa C, Procino A, Schena FP: Immunologic evaluation during the first year of life of infants born to cyclosporine treated female kidney transplant recipients. Transplantation. 2000, 69: 2049-2054. 10.1097/00007890-200005270-00013.
CAS
PubMed
Google Scholar
Cimaz R, Meregalli E, Biggioggero M, Borghi O, Tincani A, Motta M, Airo P, Meroni PL: Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy. Toxicol Lett. 2004, 149: 155-162. 10.1016/j.toxlet.2003.12.030.
CAS
PubMed
Google Scholar
Sgro MD, Barrozino T, Mirghani HM, Sermer M, Moscato L, Akoury H, Koren G, Chitayat D: Pregnancy outcome post renal transplantation. Teratology. 2002, 65: 5-9. 10.1002/tera.1092.
CAS
PubMed
Google Scholar
Jain AB, Shapiro R, Scantlebury VP, Potdar S, Jordan ML, Flohr J, Marcos A, Fung JJ: Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. Transplantation. 2004, 77: 897-902. 10.1097/01.TP.0000117564.50117.FB.
PubMed
Google Scholar
Jain AB, Reyes J, Marcos A, Mazariegos G, Eghtesad B, Fontes PA, Cacciarelli TV, Marsh JW, de Vera ME, Rafail A, et al: Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation. 2003, 76: 827-832. 10.1097/01.TP.0000084823.89528.89.
PubMed Central
CAS
PubMed
Google Scholar
Kainz A, Harabacz I, Cowlrick IS, Gadgil SD, Hagiwara D: Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation. 2000, 70: 1718-1721. 10.1097/00007890-200012270-00010.
CAS
PubMed
Google Scholar
Miniero R, Tardivo I, Curtoni ES, Segoloni GP, La Rocca E, Nino A, Todeschini P, Tregnaghi C, Rosati A, Zanelli P, Dall'Omo AM: Pregnancy after renal transplantation in Italian patients: focus on fetal outcome. J Nephrol. 2002, 15: 626-632.
PubMed
Google Scholar
French AE, Soldin SJ, Soldin OP, Koren G: Milk transfer and neonatal safety of tacrolimus. Ann Pharmacother. 2003, 37: 815-818. 10.1345/aph.1C312.
PubMed Central
PubMed
Google Scholar
Le Ray C, Coulomb A, Elefant E, Frydman R, Audibert F: Mycophenolate mofetil in pregnancy after renal transplantation: a case of major foetal malformations. Obstet Gynecol. 2004, 103: 1091-1094.
PubMed
Google Scholar
Pergola PE, Kancharla A, Riley DJ: Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. Transplantation. 2001, 71: 994-997. 10.1097/00007890-200104150-00028.
CAS
PubMed
Google Scholar
Armenti VT, Radomski JS, Gaughan WJ, Philips LZ, McGrory CH, Coscia LA, National Transplantation Registry: Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2003, 17: 131-141.
Google Scholar
Radder CM, Roelen DL, van de Meer-Prins, Claas FH, Kanhai HH, Brand A: The immunologic profile of infants born after maternal immunoglobulin treatment and intrauterine platelet transfusions for fetal/neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol. 2004, 191: 815-820. 10.1016/j.ajog.2004.02.002.
CAS
PubMed
Google Scholar
Vesga L, Terdiman JP, Mahadevan U: Adalimumab use in pregnancy. Gut. 2005, 54: 890-10.1136/gut.2005.065417.
PubMed Central
CAS
PubMed
Google Scholar
Sanchez Munoz D, Hoyas Pablos E, Ramirez Martin Del Campo M, Nunez Hospital D, Guerrero Jimenez P: Term pregnancy in a patient with Crohn's disease under treatment with adali-mumab. Gastroenterol Hepatol. 2005, 28: 435-10.1157/13077767.
CAS
PubMed
Google Scholar
Herold M, Schnohr S, Bittrich H: Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol. 2001, 19: 3439-
CAS
PubMed
Google Scholar
Kimby E, Sverrisdottir A, Elinder G: Safety of rituximabtherapy during the first trimester of pregnancy: a case history. Eur J Haematol. 2004, 72: 292-295. 10.1111/j.1600-0609.2004.00214.x.
PubMed
Google Scholar
Goroir BP, Peppel K, Silva M, Beutler B: The biosynthesis of tumor necrosis factor during pregnancy: studies with a CAT reporter transgene and TNF inhibitors. Eur Cytokine Netw. 1992, 3: 533-537.
Google Scholar
Hyrich K, Symmons D, Watson K, Silman A: Pregnancyoutcome in women who were exposed to anti-TNF agents: Results from anational population register. Arthritis Rheum.
Østensen M, Eigenmann GO: Etanercept in breast milk. J Rheumatol. 2004, 31: 1017-1018.
PubMed
Google Scholar
Treacy G: Using an analogous monoclonal antibody toevaluate the reproductive and chronic toxicity potential for a humanized anti-TNF-α monoclonal antibody. Hum Exp Toxicol. 2000, 19: 226-228. 10.1191/096032700678815765.
CAS
PubMed
Google Scholar
Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Ter-diman JP, Binion DG: Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005, 21: 733-738. 10.1111/j.1365-2036.2005.02405.x.
CAS
PubMed
Google Scholar
Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR: Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004, 99: 2385-2392. 10.1111/j.1572-0241.2004.30186.x.
PubMed
Google Scholar
Förger F, Matthias T, Oppermann M, Østensen M, Helmke K: Infliximab in breast milk. Lupus. 2004, 13: 753-10.1191/0961203304lu485oa.
Google Scholar
Mahadevan U, Terdiman JP, Aron J, Jacobsohn S, Turek P: Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis. 2005, 11: 395-399. 10.1097/01.MIB.0000164023.10848.c4.
PubMed
Google Scholar